Meet VIVEbiotech at Advanced Therapies Europe 2026
As a Bronze Sponsor, VIVEbiotech is in Barcelona connecting with industry leaders and showcasing its expertise in lentiviral vector manufacturing for innovative cell and gene therapies.
VIVEbiotech is attending Advanced Therapies Europe 2026 by Phacilitate, one of the leading events for the advanced therapies industry, taking place in Barcelona from September 7 to 9. As a Bronze Sponsor, the company joins innovators, biopharmaceutical companies, technology providers and industry experts to discuss the latest developments shaping the future of cell and gene therapies.
Visitors can meet the VIVEbiotech team at Booth #56, where Patricio Massera, Diego Bochoeyer, Natalia Elizalde and Miguel Álvarez are available to discuss the company’s ex vivo and in vivo lentiviral vector manufacturing capabilities and its role in supporting the development and commercialization of advanced therapy medicinal products. For those looking to schedule a meeting, our team is also active on the event’s partnering platform and available for one-to-one meetings.
Throughout the event, VIVEbiotech is engaging with partners, customers and industry stakeholders to explore how high-quality lentiviral vector manufacturing can help accelerate therapeutic development from early-stage research through clinical and commercial production.
A highlight of the company’s participation will be the panel discussion, “From Early Development to Commercial Readiness: Real-World Lessons in Advancing Lentiviral-Based Therapies,” taking place on September 9 from 1:30 PM to 2:30 PM.
Moderated by Patricio Massera, the session will feature experts from Kiji Therapeutics, Genewity and VIVEbiotech, and will examine key challenges and opportunities across the development pathway. Topics will include vector design, process development, GMP manufacturing, scale-up strategies, regulatory considerations and commercial readiness for lentiviral-based therapies.
Advanced Therapies Europe provides a unique event for collaboration, knowledge exchange and partnership development across the advanced therapies ecosystem. VIVEbiotech looks forward to meeting industry peers and contributing to conversations that are driving the next generation of innovative cell and gene therapies.
